

13 June 2022

Subject: Use of Biologic Medicines in Dermatology

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira 44
- Adalimumab Biosimilar 160
- Apremilast 0
- Bimekizumab 0
- Brodalumab 0
- Certolizumab 0
- Dimethyl fumarate prescribed in the community
- Etanercept – Enbrel 0
- Etanercept Biosimilar 9
- Guselkumab 84
- Infliximab – Remicade <5
- Infliximab Biosimilar 12
- Ixekizumab 46
- Risankizumab 58
- Secukinumab 40
- Tildrakizumab 6
- Ustekinumab 84

Q2. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira 16
- Adalimumab Biosimilar 13
- Filgotinib
- Golimumab
- Infliximab – Remicade 0
- Infliximab Biosimilar 8
- Ozanimod
- Tofacitinib
- Ustekinumab
- Vedolizumab
- Any other biologic drug (please name) Stelara <5